SOURCES SOUGHT
65 -- Development of Cap-Dependent Endonuclease Inhibitors for Bunyaviruses
- Notice Date
- 6/22/2023 11:12:12 AM
- Notice Type
- Sources Sought
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95023Q00421SSN
- Response Due
- 6/30/2023 9:00:00 AM
- Archive Date
- 07/15/2023
- Point of Contact
- Sarah Adan, Phone: 3014805422
- E-Mail Address
-
sarah.adan@nih.gov
(sarah.adan@nih.gov)
- Description
- This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. For equipment/supply requirements, responses must include: (1) the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture), as well as (2) the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule).� This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. �It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. �Responses will not be considered as proposals or quotes. �No award will be made as a result of this notice. �The Government will NOT be responsible for any costs incurred by the respondents to this notice. �This notice is strictly for research and information purposes only. Background:� The Antiviral Pandemic Program (APP) at the National Center for Advancing Translational Sciences (NCATS) aims to develop small molecule cap-dependent endonuclease inhibitors for bunyaviruses. Early studies found baloxavir acid, an FDA approved cap-dependent endonuclease inhibitor acid containing a divalent metal chelating pharmacophore, showed antiviral activity for certain bunyaviruses. 7 baloxavir analogs were designed which needs to be synthesized by the Contractor to test their antiviral activities against a variety of bunyaviruses including the La Crosse Encephalitis Virus (LACV) and the Rift Valley Fever Virus (RVFV). General Requirements: 1) Custom synthesis of 7 compounds;� 2) Provide 1H NMR and LCMS characterization to prove the required purity (>95%); and 3) Each compound amount >10 mg. Delivery Date: Within 4-6 weeks after receipt of order Capability statement /information sought: �Respondents must provide clear and convincing documentation of their capability of providing the equipment specified in this notice. The respondent must also provide their UEI number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing.� The information submitted must be in an outline format that addresses each of the elements of the service requirement and in the capability statement /information sought paragraphs stated herein. � The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Sarah Adan, at e-mail address sarah.adan@nih.gov, with the subject line 75N95023Q00421SSN . �� The response must be received on or before June 30, 2023, 12:00 pm, Eastern Time. Disclaimer and Important Notes: �This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work.� Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). �
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/1bdecf656c014a4fa0a0828621b957c7/view)
- Record
- SN06725529-F 20230624/230622230121 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |